By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Reaction Biology has reeled in a $1.2 million small business innovation research grant from the National Cancer Institute that it will use to expand an epigenetics-related drug discovery screening platform, the company said today.

The Malvern, Pa.-based firm plans to use the two-year grant to expand its Methyltransferase HotSpotSM drug discovery screens from 14 to 35 or more, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.